'A total of 822 participants underwent randomization, and 771 received VV116 (384 participants) or nirmatrelvir–ritonavir (387 participants). The noninferiority of VV116 to nirmatrelvir–ritonavir with respect to the time to sustained clinical recovery was established in the primary analysis'

#Antiviral #COVID19 #COVID #SARSCoV2

https://www.nejm.org/doi/full/10.1056/NEJMoa2208822?query=featured_home